These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11375381)

  • 1. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes.
    Hedman CA; Lindström T; Arnqvist HJ
    Diabetes Care; 2001 Jun; 24(6):1120-1. PubMed ID: 11375381
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
    Homko C; Deluzio A; Jimenez C; Kolaczynski JW; Boden G
    Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of lipoatrophy with Lispro insulin without insulin pump therapy.
    Arranz A; Andia V; López-Guzmán A
    Diabetes Care; 2004 Feb; 27(2):625-6. PubMed ID: 14747261
    [No Abstract]   [Full Text] [Related]  

  • 5. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effects and pharmacodynamics of insulin analogs lispro, aspart and glargin].
    Heinemann L; Heise T
    Dtsch Med Wochenschr; 2001 May; 126(20):597-604. PubMed ID: 11402927
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Wittlin SD; Marcus AO; Weng CS; Howard CP; Schorr AB;
    Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
    Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T
    Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe insulin resistance treated with insulin lispro.
    Gill G; Williams G
    Lancet; 1997 Jan; 349(9046):211. PubMed ID: 9111571
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired absorption of insulin aspart from lipohypertrophic injection sites.
    Johansson UB; Amsberg S; Hannerz L; Wredling R; Adamson U; Arnqvist HJ; Lins PE
    Diabetes Care; 2005 Aug; 28(8):2025-7. PubMed ID: 16043749
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical aspects of Insulin Lispro (LY275585)].
    Kuzuya T
    Nihon Rinsho; 1997 Nov; 55 Suppl():298-305. PubMed ID: 9434484
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects.
    Gupta J; Felner EI; Prausnitz MR
    Diabetes Technol Ther; 2011 Apr; 13(4):451-6. PubMed ID: 21355717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in insulin therapy].
    Tajuma N
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1888-94. PubMed ID: 17037332
    [No Abstract]   [Full Text] [Related]  

  • 16. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
    Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
    Lindström T; Hedman CA; Arnqvist HJ
    Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
    Rassam AG; Zeise TM; Burge MR; Schade DS
    Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.